Abeona Therapeutics Inc. (ABEO)
$
4.36
-0.20 (-4.59%)
Key metrics
Financial statements
Free cash flow per share
-1.3573
Market cap
223.6 Million
Price to sales ratio
43.1435
Debt to equity
0.1472
Current ratio
6.7289
Income quality
-1.1526
Average inventory
1.3 Million
ROE
0.7768
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases, reported depreciation and amortization expenses of $2,907,000.00 reflecting the wear and tear of its assets. The company demonstrated its financial health with an income before tax of -$63,734,000.00 showcasing its pre-tax profitability. With a weighted average number of diluted shares outstanding of $41,048,000.00 the company highlights potential dilution effects that could arise. Operating expenses were also noted, as the company reported selling, general, and administrative expenses of $29,851,000.00 indicating its operational overhead costs. Furthermore, the weighted average number of shares outstanding is $41,048,000.00 which underscores the company’s shareholder base and their potential influence on its market strategies. Abeona's lead program, EB-101, is an autologous, gene-corrected cell therapy currently in Phase III clinical trials for recessive dystrophic epidermolysis bullosa, while the company is also advancing other therapeutic candidates targeting conditions such as Sanfilippo syndrome type A and cystic fibrosis. Within the financial landscape, the stock is affordable at $5.38 suitable for budget-conscious investors. However, it is noteworthy that the stock has a low average trading volume of $1,067,068.00 indicating lower market activity which may affect liquidity. With a market capitalization of $223,569,455.00 the company is classified as a small-cap player in the biopharmaceutical field. As a key player in the Biotechnology industry, Abeona contributes significantly to the overall market landscape, particularly through its innovative approaches to treating rare genetic disorders. Additionally, it belongs to the Healthcare sector, continuously driving innovation and growth within this vital area of healthcare. The ongoing development of its AAV-based gene therapy programs through the AIM vector platform exemplifies Abeona’s commitment to pioneering treatments, further enhancing its role in the evolving biopharmaceutical industry.
Is Abeona Therapeutics Inc. (ABEO) a good investment?
Investing in Abeona Therapeutics Inc. (ABEO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A-, with a Bearish outlook. Always conduct your own research before investing.
What is Abeona Therapeutics Inc. (ABEO)'s stock forecast?
Analysts predict Abeona Therapeutics Inc. stock to fluctuate between $3.93 (low) and $7.54 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Abeona Therapeutics Inc.'s market capitalization?
As of 2025-11-05, Abeona Therapeutics Inc.'s market cap is $223,569,455, based on 51,277,398 outstanding shares.
How does Abeona Therapeutics Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Abeona Therapeutics Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Abeona Therapeutics Inc. pay dividends?
Abeona Therapeutics Inc. pays dividends. The current dividend yield is 8.55%, with a payout of $0.59 per share.
How can I buy Abeona Therapeutics Inc. (ABEO) stock?
To buy Abeona Therapeutics Inc. (ABEO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABEO. Place an order (Market, Limit, etc.).
What is the best time to invest in Abeona Therapeutics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Abeona Therapeutics Inc. stock ever split?
Abeona Therapeutics Inc.'s last stock split was 1:25 on 2022-07-05.
How did Abeona Therapeutics Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.55 | Growth: -38.74%.
Where can I find Abeona Therapeutics Inc.'s investor relations reports?
Visit https://www.abeonatherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Abeona Therapeutics Inc.?
You can explore historical data from here
What is the all-time high and low for Abeona Therapeutics Inc. stock?
All-time high: $34 (2021-09-02) | All-time low: $2.19 (2023-02-24).
What are the key trends affecting Abeona Therapeutics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets, the Company's autologous gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The new J-code for ZEVASKYN, J3389 (Topical administration, prademagene zamikeracel, per treatment) becomes effective on January 1, 2026.
globenewswire.com
CLEVELAND, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of Clinical Development & Medical Affairs, effective immediately.
globenewswire.com
RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies RDEA Pilot Program provides sponsors enhanced communication and collaboration with FDA to accelerate development of rare disease therapies
globenewswire.com
CLEVELAND, Ohio and AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Children's Hospital Colorado today announced activation of Children's Colorado as the newest Qualified Treatment Center (QTC) for ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Children's Colorado in Aurora, CO, one of the pioneering institutions that provide advanced levels of care for people with epidermolysis bullosa (EB), has completed QTC start-up activities enabling it to begin patient identification for scheduling of ZEVASKYN treatment.
globenewswire.com
CLEVELAND, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2025:
seekingalpha.com
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Brian Kevany - Senior VP, CTO & CSO Gregory Gin - Vice President of Investor Relations & Corporate Communications Joseph Walter Vazzano - Chief Financial Officer Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Vishwas Seshadri - President, CEO & Director Conference Call Participants James Francis Molloy - Alliance Global Partners, Research Division Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Operator Good Day everyone, and welcome to the Abeona Therapeutics Second Quarter 2025 Conference Call.
seekingalpha.com
The FDA's approval and commercial launch of Abeona Therapeutics Inc.'s Zevaskyn for RDEB, plus $155M PRV sale, provides strong financial runway for company for two years. AIM AAV204 capsid platform and ABO-503 gene therapy offer differentiated potential in rare eye disorders, with key catalysts in 2025-2026. ABEO expansion opportunities exist via licensing deals, notably with Beacon Therapeutics, and broader application of the AIM capsid library towards other indications.
globenewswire.com
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
globenewswire.com
- Lucile Packard Children's Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - - ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of the newest Qualified Treatment Center (QTC) for FDA-approved ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy, an outcome of a decade of research by Abeona and two decades of research at Stanford Medicine, where the technology originated, will be used to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).
globenewswire.com
Cash resources totaled approximately $225 million as of June 30, 2025 Cash resources totaled approximately $225 million as of June 30, 2025
See all news
